Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Completed 22 enrolled National Cancer Institute (NCI)

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Akt inhibitor MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2011-12
Primary completion: 2013-06
Completion: 2014-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-2206	Small molecule	—	Oral

Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Summary

Timeline

Drugs

Indications